QL-47

Research use only, not for human use.

A potent, selective, and irreversible BTK inhibitor with IC50 of 7 nM.

A potent, selective, and irreversible BTK inhibitor with IC50 of 7 nM; inhibits BTK kinase activity with an IC50 of 7 nM, inhibits autophosphorylation of BTK on Tyr223 in cells with an EC50 of 475 nM, and inhibits phosphorylation of a downstream effector PLCγ2 (Tyr759) with an EC50 of 318 nM; induces a G1 cell cycle arrest that is associated with pronounced degradation of BTK protein in Ramos cells; inhibits the proliferation of B-cell lymphoma cancer cell lines at submicromolar concentrations. Blood Cancer Preclinical.

QL47 inhibits protein neosynthesis initiated by both canonical cap-driven and noncanonical initiation strategies, most likely by targeting an early step in translation elongation.QL47 inhibits autophosphorylation of BTK on Tyr223 in cells with an EC50 of 475 nM, and inhibits phosphorylation of a downstream effector PLCγ2 (Tyr759) with an EC50 of 318 nM. In Ramos cells QL47 induces a G1 cell cycle arrest that is associated with pronounced degradation of BTK protein. QL47 inhibits the proliferation of B-cell lymphoma cancer cell lines at submicromolar concentrations.

——

QL47 | QL 47 | QL47. QL-XII-47

Tyrosine Kinase

BTK

BTK

Cancer

Blood cancer

1469988-75-7

447.4879

C27H21N5O2

>98% (HPLC)

DMSO: < 9.4 mg/mL

O=C1N(C2=CC3=C(C=C2)CCN3C(C=C)=O)C4=C(C=NC5=CC=C(C6=CN(C)N=C6)C=C54)C=C1

Benzo[h]-1,6-naphthyridin-2(1H)-one, 1-[2,3-dihydro-1-(1-oxo-2-propen-1-yl)-1H-indol-6-yl]-9-(1-methyl-1H-pyrazol-4-yl)-

(-20℃)

With Ice Pack

≥ 2 years